Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo
Crossref DOI link: https://doi.org/10.1007/s10120-014-0391-x
Published Online: 2014-06-24
Published Print: 2015-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Poole, Chris D.
Connolly, Mark P.
Chang, Jane
Currie, Craig J.
License valid from 2014-06-24